galcanezumab   Click here for help

GtoPdb Ligand ID: 8967

Synonyms: clone III | Emgality® | galcanezumab-gnlm | LY-2951742 | LY2951742
Approved drug Immunopharmacology Ligand
galcanezumab is an approved drug (FDA (2018))
Compound class: Antibody
Comment: Galcanezumab (LY2951742) is a monoclonal antibody targeting calcitonin A and B (CALCA a.k.a. α-CGRP and CALCB a.k.a. β-CGRP respectively), whose anti-migraine and analgesic actions can be applied clinically.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent WO2007076336 [1].
Bioactivity Comments
A Fab fragment of the antibody binds human αCGRP with a Kd of 2.09nM and the β isoform with a Kd of 1.22nM [1].
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
α-CGRP Rn Antibody Binding 9.9 pKd - 1
pKd 9.9 (Kd 1.27x10-10 M) [1]
α-CGRP Primary target of this compound Hs Antibody Binding 8.7 pKd - 1
pKd 8.7 (Kd 2.2x10-9 M) [1]